Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
1999 3
2000 6
2001 12
2002 11
2003 4
2004 3
2005 2
2006 8
2007 6
2008 6
2009 7
2010 7
2011 7
2012 7
2013 2
2014 5
2015 3
2016 1
2017 4
2018 2
2019 2
2020 3
2021 3
2022 3
2023 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: kalbakis k. Cancer Chemother Pharmacol. 2011 Jul;68(1):217-23. doi: 10.1007/s00280-010-1475-x. Epub 2010 Oct 5. Cancer Chemother Pharmacol. 2011. PMID: 20922389 Clinical Trial.
Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. Saloustros E, et al. Among authors: kalbakis k. Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24. Clin Breast Cancer. 2018. PMID: 29153775 Clinical Trial.
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V. Xenidis N, et al. Among authors: kalbakis k. Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17. Br J Cancer. 2013. PMID: 23329233 Free PMC article.
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Apostolaki S, et al. Among authors: kalbakis k. Ann Oncol. 2007 May;18(5):851-8. doi: 10.1093/annonc/mdl502. Epub 2007 Feb 14. Ann Oncol. 2007. PMID: 17301075 Free article.
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D. Georgoulias V, et al. Among authors: kalbakis k. Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344760 Clinical Trial.
105 results